Impact of CArdiopulmonary Bypass Flow on Renal Blood Flow, Function and OXygenation

NACompletedINTERVENTIONAL
Enrollment

18

Participants

Timeline

Start Date

January 31, 2016

Primary Completion Date

June 30, 2017

Study Completion Date

August 31, 2017

Conditions
Complication of Extracorporeal CirculationKidney Circulation DisorderRenal Function Disorder
Interventions
PROCEDURE

Increased cardiopulmonary bypass flow

In randomized order, CPB flow will be adjusted to 2,4, 2,7 and 3,0 L/min/m2. After 10 minutes of steady conditions at each level, measurements will be made.

DRUG

Milrinone

"After weaning from CPB, patients with signs of cardiac failure (as defined below) will be given milrinone (0,04 mg/kg as a loading dose and 0,50 ug/kg/min as subsequent infusion). Measurements of systemic and renal variables will be made before and 30 minutes after the dose.~Indication: Central venous pressure (CVP) ≥ 12 mmHg AND/OR Pulmonary Capillary Wedge Pressure (PCWP) ≥ 16 mmHg AND Cardiac Index (CI) ≤ 2,1 L/min/m2 AND Pulse Pressure Variation (PPV) \< 12 %."

Trial Locations (1)

41345

Department of thoracic anesthesia, Sahlgrenska University Hospital, Gothenburg

All Listed Sponsors
lead

Sahlgrenska University Hospital

OTHER

NCT02549066 - Impact of CArdiopulmonary Bypass Flow on Renal Blood Flow, Function and OXygenation | Biotech Hunter | Biotech Hunter